In June 2020, we failed to report on the ARD publication updating the 2019 update the European League Against Rheumatism (EULAR) recommendations for the pharmacological treatment of psoriatic arthritis (PsA) - these are presented below.
A phase II study of patients with early diffuse systemic sclerosis (SSc) has demonstrated improvement in SSc skin outcomes by targeting T cells and fibrosis with the bispecific monoclonal antibody romilkimab (RMK).
JAMA Dermatology reports a claims-based, case-time-controlled French study of 9290 psoriasis patients suggesting that ustekinumab initiation may be associated with an increased risk of acute coronary syndrome or stroke in high risk cardiovascular patients.
JAMA Dermatology expands the spectrum of complications seen with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection describing cutaneous purpura and livedo lesions in patients with severe COVID-19.
Asymptomatic people who have been exposed to COVID-19 should be tested, the CDC said on Friday, in a reversal of controversial guidance the agency introduced in late August.
Research from Oxford University suggests a potential pathogenic role for the chemokine CXCR3 and clonally restricted CD8+ T cells in the pathogenesis of psoriatic arthritis (PsA) based studies of PsA synovial fluid samples obtained by arthrocentesis from 11 patients with large-joint oligo Ps
Patients with RA have up to a three-fold increased risk of mortality versus the general population, largely due to an increased incidence of premature CVD, such as atherosclerosis and heart failure.
Dr Jack Cush reviews the news and journal reports from the past week on RheumNow.com:
There has been little science or evidence regarding the effects of COVID-19 infection on pregnancy and vice versa; and now the recent MMWR addresses the subject with two new reports
The MIRROR study, an open-label pilot trial in refractory, uncontrolled gout patients, showed that pegloticase given in combination with methotrexate was safe and effective and maintained responses for 6 months after initiation.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
